Every Form 4 that Astera Labs (ALAB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALAB filings page.
Astera Labs, Inc. (ALAB) director Stefan A. Dyckerhoff reported selling a total of 12,499 shares of common stock on September 2, 2026, in open-market transactions at weighted average prices between about $273 and $277 per share. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025. Portions of the shares were held directly, while others were held indirectly through a trust and a limited partnership, and certain indirect positions and irrevocable trusts are reported with the filer disclaiming beneficial ownership except for his pecuniary interest.
Astera Labs, Inc. (ALAB) director Manuel Alba reported that entities associated with him sold a total of 183,000 shares of Common Stock on September 1, 2026. The sales were executed indirectly through the Alba 2003 Living Trust and Casa Alameda 2007, LLC at weighted average prices ranging from about $276.72 to $288.99 per share.
The trades occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026. After these transactions, Alba also reports indirect ownership of 5,000 shares through his spouse and direct ownership of 2,351 shares, while disclaiming beneficial ownership of the trust and LLC shares except for any pecuniary interest.
Astera Labs, Inc. (ALAB) reported that President and COO Gajendra Sanjay sold an aggregate 90,630 shares of Common Stock on August 17, 2026. The company states these shares were sold automatically under a pre-established “sell to cover” arrangement to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units, and that the transactions did not represent discretionary trades by the executive.
Weighted-average sale prices for the blocks ranged from about $333.60 to $352.11 per share, each over narrower intraday price ranges described in the footnotes. In addition, indirect holdings reported for estate-planning vehicles included 5,290,402 shares held by Trust 1, and 615,000 shares each held by Trust 2 and Trust 3, for which Sanjay disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. (ALAB) reported that its General Counsel and Secretary, Philip Mazzara, had multiple sales of common stock on August 17, 2026. In total, 6,801 shares were sold in open-market block trades at reported per-share prices between $333.6377 and $352.1027.
According to the company’s disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units. The company states the sales were automatic under a pre-established “sell to cover” election made by Astera Labs and did not represent discretionary trading by Mazzara.
Astera Labs, Inc. (ALAB) reported that Chief Executive Officer and director Jitendra Mohan executed multiple sales of the company’s Common Stock on August 17, 2026. In total, 90,630 shares were sold in a series of open-market block trades at weighted-average prices generally between the mid-$330s and mid-$350s per share. According to the disclosure, these shares were required to be sold to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units, under an advance “sell to cover” election made by Astera Labs; the filing states these were not discretionary trades by Mohan. The filing also lists significant indirect holdings in various estate-planning and living trusts, including positions such as 699,999 shares held by an estate planning trust and 3,789,232 shares held by a living trust, for which Mohan disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. director Stefan A. Dyckerhoff reported sales of 12,499 shares of common stock on 2026-08-06. The shares were sold in multiple open-market transactions at weighted average prices around $309–$313 per share, pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025. Some shares were held directly, while others were held through trusts and a limited partnership for which he serves as trustee or through related roles, and he disclaims beneficial ownership beyond his pecuniary interest.
Cota Germaine reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs, Inc. granted Chief Accounting Officer and VP, Finance Germaine Cota an award of 1,451 restricted stock units of common stock on July 20, 2026 under its 2024 Stock Option and Incentive Plan. Following this award, Cota directly holds 26,440 shares of common stock.
The award provides that 6.25% of the RSUs shall vest in 16 equal quarterly installments after the vesting commencement date of August 15, 2026, conditioned on a continuous service relationship with the company. Each RSU represents a contingent right to receive one share of common stock.
Astera Labs director Manuel Alba reported pre-planned insider sales tied to an affiliated entity. On July 1, 2026, Casa Alameda 2007, LLC, of which Alba is a manager, sold 8,491 shares of Astera Labs common stock in multiple open-market transactions under a Rule 10b5-1 trading plan adopted on May 29, 2025.
The Form 4 notes weighted average sale prices, with individual trades executed in ranges from $451.4600 to $468.0000 per share. After these transactions, Casa Alameda 2007, LLC held 286,863 shares indirectly, while Alba also reported 2,351 shares held directly and 5,000 shares held indirectly by his spouse. Alba disclaims beneficial ownership of the LLC-held shares except to the extent of any pecuniary interest.
Astera Labs, Inc. director Manuel Alba reported a series of automatic, pre-planned stock sales linked to entities associated with him. On July 1, 2026, Casa Alameda 2007, LLC and the Alba 2003 Living Trust together sold 37,535 shares of Astera Labs common stock in 29 open-market transactions.
The filing states these sales occurred automatically under a Rule 10b5-1 trading plan adopted on May 29, 2025. Alba disclaims beneficial ownership of the securities held by Casa Alameda 2007, LLC and by the Alba Trust, except to the extent of any pecuniary interest.
Astera Labs director-related trust reports pre-planned stock sales. Alba 2003 Living Trust, associated with director Manuel Alba, sold a total of 136,974 shares of Astera Labs common stock on July 1, 2026 in multiple open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
The reported sale prices ranged from $429.11 to $459.44 per share, based on weighted-average pricing disclosures. Following these transactions, the trust continues to hold 1,287,524 shares of Astera Labs common stock indirectly for the benefit of the Alba 2003 Living Trust, with Manuel Alba-Marquez and his spouse as co-trustees, and Manuel Alba disclaiming beneficial ownership except to the extent of any pecuniary interest.
Astera Labs, Inc. director Stefan A. Dyckerhoff reported planned stock sales through various entities. On 2026-07-01, entities associated with him sold a total of 12,499 shares of Astera Labs common stock at $450.00 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
The sales included 3,505 shares from his direct holdings, 8,333 shares held by a trust, and 661 shares held by a limited partnership. After these transactions, reported positions include 57,466 shares held directly, 311,399 shares held by a trust, 4,631 shares held by a limited partnership, and several smaller indirect holdings, with Dyckerhoff disclaiming beneficial ownership except for his pecuniary interests.
Astera Labs, Inc. director Bethany Mayer reported open-market sales of 686 shares of Common Stock on June 24, 2026. The transactions were executed in multiple tranches at weighted average prices reported between $391.2689 and $399.9600, with underlying trade ranges from $391.1300 to $398.6100 as described in the footnotes.
The sales occurred automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2024. Following these transactions, Mayer holds 5,550 shares directly and 839 shares indirectly through The Jantzen/Mayer Family 2002 Trust, for which she disclaims beneficial ownership beyond any pecuniary interest.
Astera Labs director Jack R. Lazar reported net share sales and an equity grant. On June 4, 2026 he sold 10,000 shares of Common Stock in open-market transactions under a Rule 10b5-1 trading plan at prices between $339.5600 and $362.8405 per share, and now directly holds 75,688 shares. He also received a grant of 837 restricted stock units that vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service.
Astera Labs, Inc. director Michael E. Hurlston received an equity award of 837 shares of common stock in the form of restricted stock units (RSUs) on June 4, 2026. After this grant, he holds 92,482 shares directly, including deferred stock units and dividend equivalent units. The RSU award will vest in full on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues his service. Each RSU converts into one share of Astera Labs common stock when it vests.
BARRATT CRAIG H reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs, Inc. director Craig H. Barratt received an award of 837 restricted stock units on June 4, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continuous service with the company through the vesting date. Following this grant, Barratt directly holds 6,825 shares of common stock.
Mayer Bethany reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs director Bethany Mayer received an equity award and reported trust holdings. She was granted 837 restricted stock units (RSUs) of Astera Labs, Inc. common stock on June 4, 2026 under the company’s 2024 Stock Option and Incentive Plan.
The RSU award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continuous service. After this grant, she holds 6,236 shares directly. A separate 839 Astera Labs shares are held indirectly by The Jantzen/Mayer Family 2002 Trust, where she is a trustee and disclaims beneficial ownership except for any pecuniary interest.
Astera Labs director Stefan Dyckerhoff reported a mix of stock sales and an equity grant. Entities associated with him, including a trust and a limited partnership, sold a total of 12,499 shares of Astera Labs common stock on June 3, 2026 at weighted average prices of $364.246 and $365.087 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. After these transactions, individual records show continued substantial direct and indirect holdings through these entities.
On June 4, 2026, Dyckerhoff also received an award of 837 restricted stock units that will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service. Following the grant, he directly holds 60,971 shares of common stock, with additional indirect holdings held through various trusts and partnerships in which he has a pecuniary interest.
Astera Labs, Inc. President and COO Gajendra Sanjay reported pre-planned stock sales and estate-planning transfers involving the company’s common stock. An estate planning trust referred to as "Trust 1" sold a total of 400,000 shares on May 21, 2026 in a series of open-market transactions at weighted average prices in ranges from about $288.80 to $293.50 per share, executed under a Rule 10b5-1 trading plan adopted on December 2, 2025.
The filing also shows bona fide gifts totaling 452,378 shares, including a transfer of 226,189 shares of common stock to Trust 1 for no consideration as part of estate planning. After these transactions, Sanjay holds 1,209,668 shares directly, while Trust 1 holds 5,290,402 shares, and additional 615,000-share positions are reported for separate estate planning trusts labeled Trust 2 and Trust 3, for which beneficial ownership is disclaimed except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported an open-market sale of 796 shares of Common Stock on May 21, 2026, at an average price of $291.0251 per share. Following this transaction, he continues to hold 103,343 shares directly.
Astera Labs, Inc. director and President & COO Gajendra Sanjay reported pre-planned sales of common stock tied to his estate planning trusts. On May 19, 2026, three trusts labeled Trust 1, Trust 2, and Trust 3 sold a combined 280,000 shares of Astera Labs common stock in open-market transactions.
The sales were executed automatically under a Rule 10b5-1 trading plan adopted by Sanjay on December 2, 2025. Reported weighted average sale prices ranged from about $248.40 to $251.80 per share. Following these transactions, Trust 1 held 5,464,213 shares, Trust 2 held 615,000 shares, and Trust 3 held 615,000 shares, while Sanjay also held 1,435,857 shares directly.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported automatic sales of 95,444 shares of common stock. According to the disclosure, these shares were required to be sold to satisfy tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units and were executed under a pre‑elected "sell to cover" arrangement, not as discretionary trades.
Following these transactions, he continues to hold 1,357,295 shares of common stock directly, along with additional indirect holdings through several estate planning and living trusts.
Astera Labs, Inc. President and COO Gajendra Sanjay reported automatic tax-related share sales. On 2026-05-18, Form 4 shows the sale of 95,444 shares of Astera Labs common stock in multiple open-market transactions at prices between $216.10 and $235.94 per share.
According to a footnote, these sales were required to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units and were executed under a pre-arranged “sell to cover” election, rather than as discretionary trades. Additional entries show large indirect holdings in three estate planning trusts, for which Sanjay disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported automatic sales of company stock tied to tax withholding. On May 18, 2026, he sold a total of 14,076 shares of Astera Labs common stock in open-market transactions.
According to the footnotes, these shares were required to be sold to satisfy tax withholding obligations from the vesting and settlement of previously granted restricted stock units. The company had elected in advance to use a “sell to cover” method, so the trades were automatic rather than discretionary. The shares were sold at weighted-average prices within ranges that span from about $216.10 to $235.94 per share.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported open‑market sales of 139,951 shares of Common Stock, carried out on behalf of a living trust. The sales occurred at weighted average prices within ranges between $210.0564 and $250.0100 per share.
The filing states these transactions were executed automatically under a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2025. The shares are held through a living trust and several estate planning trusts, for which the reporting person disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara acquired additional company stock through an employee purchase program. On May 14, 2026, he received 131 shares of common stock at $120.1815 per share under the 2024 Employee Stock Purchase Plan, bringing his direct holdings to 118,215 shares. The filing notes these plan purchases were exempt under Rule 16b-3(d) and Rule 16b-3(c).
Astera Labs, Inc. director and President/COO Gajendra Sanjay reported insider sales executed through estate-planning trusts. On May 7, 2026, trusts identified as "Trust 2" and "Trust 3" sold an aggregate of 49,361 shares of Common Stock in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
The reported weighted average sale prices span ranges disclosed in multiple footnotes, including transactions within bands such as $192.4400 to $193.4300 and up to higher ranges reflected in individual line items. Following these transactions, Sanjay continues to hold 1,531,301 shares directly, while the trusts still hold over 650,000 shares each. The filing states that the shares in Trust 2 and Trust 3 are owned directly by estate planning trusts, and Sanjay disclaims beneficial ownership except to the extent of any pecuniary interest.
Astera Labs, Inc. estate planning trusts reported sizeable planned share sales. On May 7, 2026, trusts associated with President and COO Gajendra Sanjay sold a total of 230,639 shares of Astera Labs common stock in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025. Individual blocks were sold at prices including $198.8237 and $213.49 per share. After these sales, one estate planning trust (Trust 1) reported holding 5,859,488 shares, while a second trust (Trust 2) reported holding 694,055 shares. The filing states that Sanjay disclaims beneficial ownership of these trust-held securities except to the extent of any pecuniary interest.
Astera Labs, Inc.’s CEO Mohan Jitendra reported multiple open-market sales of Common Stock on May 7, 2026, totaling 139,951 shares. The transactions were executed by a living trust associated with him under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.
Sale prices ranged around $199–$206 per share, reported as weighted averages across several trades. After these sales, the living trust still held 3,929,183 shares of Astera Labs Common Stock, while Jitendra also held additional shares directly and through several estate planning trusts.
Astera Labs director Stefan A. Dyckerhoff reported open-market sales totaling 12,499 shares of Common Stock on May 7, 2026. The shares were sold at weighted-average prices of $201.102 and $199.00 per share under a Rule 10b5-1 trading plan adopted on December 1, 2025.
After these sales, Dyckerhoff holds 65,361 shares directly and additional indirect positions, including 332,160 shares held by a trust and 6,278 shares held by a limited partnership, where he disclaims beneficial ownership except for his pecuniary interest.
Lynch Desmond reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs, Inc. Chief Financial Officer Desmond Lynch reported two equity awards of common stock. On May 1, 2026, he received grants classified as awards of restricted stock units (RSUs) under the company’s 2024 Stock Option and Incentive Plan.
One award for 7,083 RSUs vests 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments thereafter, subject to his continuous service. A second award for 42,501 RSUs vests 100% on February 15, 2027, also contingent on ongoing service. Each RSU represents the right to receive one share of Astera Labs common stock, and the transactions were recorded at a grant price of $0.00 per share, reflecting compensation rather than open-market buying.
Astera Labs, Inc. director and CEO Mohan Jitendra reported that a living trust associated with him sold 335,881 shares of Common Stock in open-market transactions. The sales occurred on April 17 and April 20, 2026 at weighted average prices generally in the high $160s to mid-$170s per share.
The transactions were executed automatically under a Rule 10b5-1 trading plan adopted on December 1, 2025. The filing notes that the shares are held by a living trust and other estate planning trusts, and Jitendra disclaims beneficial ownership of these securities except to the extent of any pecuniary interest, while still reporting more than 4.3 million shares held indirectly after the sales.
Astera Labs, Inc. director Stefan A. Dyckerhoff reported open-market sales of Astera Labs common stock totaling 24,998 shares. The transactions on April 17 and April 20, 2026 were executed at weighted average prices around $175.00–$175.51 per share.
Entities associated with Dyckerhoff, including a trust and a limited partnership, sold shares, and he also sold shares held directly. Footnotes state the shares held by these entities are in trusts and a partnership where he disclaims beneficial ownership except for his pecuniary interest.
The filing notes that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
Astera Labs, Inc. Chief Executive Officer Mohan Jitendra, through a living trust, reported open-market sales of Common Stock. On April 15, 2026, the living trust sold 2,767 shares at $174.5682 per share and 200 shares at $175.03 per share.
The filing states these sales occurred automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025, indicating they were scheduled in advance. Following the trades, the living trust holds 4,405,015 shares, and the filing also lists additional indirect holdings in multiple estate-planning trusts and a direct holding of 1,452,739 shares of Common Stock.
Astera Labs, Inc. reported that a living trust associated with Chief Executive Officer Mohan Jitendra sold 123,750 shares of Common Stock in open-market transactions. The trust sold 99,023 shares at a weighted average price of $149.5322 per share and 24,727 shares at a weighted average price of $150.2535 per share.
The filing states these sales occurred automatically under a Rule 10b5-1 trading plan adopted on December 1, 2025. After the sales, the living trust reported holding 4,407,982 shares indirectly, and the filing also lists additional indirect holdings in several estate planning trusts and 1,452,739 shares held directly.
Astera Labs, Inc. director Manuel Alba reported that entities associated with him executed open-market sales of 183,000 shares of Astera Labs common stock on April 1, 2026. The trades were carried out automatically under a Rule 10b5-1 trading plan adopted on May 29, 2025, at weighted-average prices between approximately $105.85 and $111.27 per share.
After these sales, the Alba 2003 Living Trust held 1,424,498 shares, Casa Alameda 2007, LLC held 319,863 shares, Alba’s spouse held 5,000 shares, and he held 2,351 shares directly. The filing notes that Alba disclaims beneficial ownership of the trust and LLC shares beyond any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara sold a total of 10,000 shares of common stock in open-market transactions on April 1, 2026, at weighted average prices ranging from just over $105 to about $111 per share.
The filing notes these sales occurred automatically under a pre-arranged Rule 10b5-1 trading plan adopted on May 29, 2025. Following the transactions, Mazzara continues to hold 118,584 shares of Astera Labs common stock directly.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported that a living trust associated with him sold 157,500 shares of common stock in open-market transactions on March 17, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.
The sales were executed indirectly through the living trust at weighted-average prices generally between about $125 and $135 per share, in multiple tranches. After these transactions, the filing shows the living trust holding 4,531,732 shares, and it also lists additional indirect holdings in several estate planning trusts and 1,452,739 shares held directly, with Jitendra disclaiming beneficial ownership of the trust-held shares except for any pecuniary interest.
Astera Labs, Inc. director Jack R. Lazar reported an open-market sale of 2,500 shares of Common Stock at $130.0000 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
Following this sale, Lazar directly holds 84,851 shares of Astera Labs Common Stock, so the transaction represents a small portion of his reported holdings and appears to be a routine, pre-planned disposition rather than a discretionary trade.
Astera Labs, Inc. director Jack R. Lazar reported selling a total of 7,500 shares of common stock in open-market transactions on March 5, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
The weighted average sale prices ranged from about $117.64 to $123.50 per share across multiple trades. After these transactions, Lazar directly holds 87,351 shares of Astera Labs common stock.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported open-market sales of 10,000 shares of common stock on March 2, 2026. The transactions were carried out in multiple tranches at weighted average prices ranging from about $113.37 to $120.99 per share.
The filing notes that all sales occurred automatically under a pre-established Rule 10b5-1 trading plan adopted on May 29, 2025, which is designed to systematically execute trades over time. Following these sales, Mazzara directly owns 128,084 shares of Astera Labs common stock.
Astera Labs, Inc. Chief Executive Officer Mohan Jitendra reported automatic sales of 94,971 shares of common stock on February 17, 2026. The filing states these shares were sold to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units under a pre-arranged “sell to cover” election, and it notes the transactions were not discretionary trades by the reporting person.
After these sales, Jitendra continues to hold 1,452,739 shares of common stock directly. The filing also reports additional indirect holdings through a living trust and several estate-planning trusts, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Astera Labs, Inc. President and COO Gajendra Sanjay reported open-market sales of 94,971 shares of common stock on February 17, 2026. The shares were sold at weighted-average prices between $122.1576 and $126.3400 per share.
According to the disclosure, these shares were required to be sold to satisfy tax withholding obligations tied to vesting and settlement of previously granted restricted stock units, under a pre-arranged “sell to cover” election, and do not represent discretionary trades by Sanjay.
After these sales, he holds 1,531,301 shares directly. Estate-planning trusts associated with him hold an additional 5,864,213 shares in Trust 1, 695,000 shares in Trust 2, and 695,000 shares in Trust 3, for which he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. Chief Financial Officer Michael Truett reported automatic sales of 12,001 shares of common stock on February 17, 2026 to satisfy tax withholding from vested restricted stock units under a pre-arranged sell-to-cover election. Sale prices ranged around $122–$126 per share. Truett continues to hold 192,083 shares directly, while 450,281 additional shares are held by the Tate 1997 Living Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported automatic sales of 4,849 shares of common stock on February 17, 2026. The Form 4 notes these open-market sales were made solely to cover tax withholding obligations from vesting restricted stock units. After these transactions, he directly held 138,084 shares of common stock.
Astera Labs, Inc. reported an equity award for its Chief Financial Officer, Tate Michael Truett. On February 6, 2026, he received 11,787 restricted stock units of Common Stock at a price of $0 per share, increasing his directly held Common Stock to 204,084 shares.
The RSUs vest 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, conditioned on his continued service. Separately, 450,281 Common Stock shares are held indirectly by the Tate 1997 Living Trust, where he is a trustee and disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. insider filing shows new equity compensation for a senior executive. President and COO, and director, Gajendra Sanjay received 26,522 restricted stock units (RSUs) of common stock on February 6, 2026 at a stated price of $0.
The RSUs vest 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, contingent on his continued service. Following this award, he directly beneficially owns 1,626,272 common shares. Additional common shares are held through three separate estate-planning trusts, where he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. reported an equity grant to its Chief Executive Officer and director, Mohan Jitendra. On February 6, 2026, he received 26,522 shares of common stock as restricted stock units at $0 per share under the 2024 Stock Option and Incentive Plan.
The RSUs vest as to 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, contingent on continued service. Following this grant, he directly holds 1,547,710 shares of common stock. Additional common shares are held indirectly through a living trust and several estate-planning trusts that are associated with him, for which he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. reported that its General Counsel and Secretary, Philip Mazzara, received an equity award in the form of restricted stock units. On February 6, 2026, he was granted 5,893 RSUs at a price of $0 per share under the 2024 Stock Option and Incentive Plan.
These RSUs vest 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, as long as he continues his service with the company. Each RSU converts into one share of common stock upon vesting, bringing his directly owned common shares to 142,933 after this grant.
Astera Labs, Inc. reported that Chief Accounting Officer and VP, Finance Cota Germaine received two equity awards on February 2, 2026. The awards total 24,933 restricted stock units (RSUs), each RSU representing one share of common stock.
One grant covers 21,817 RSUs that vest 25% on February 15, 2027, with the remaining 75% vesting in 12 equal quarterly installments afterward, contingent on continued service. A second grant of 3,116 RSUs vests 100% on February 15, 2027, also subject to ongoing service. Following these grants, Germaine directly holds 24,989 shares of common stock.
Astera Labs, Inc.'s director and President & COO reported gifting common stock held through an estate-planning trust. On 12/01/2025 and 12/02/2025, a trust labeled “Trust 1” made two bona fide gifts of 71,000 shares each of Astera Labs common stock, reported at a price of $0 per share using transaction code G for gifts.
Following these transactions, the reporting person is shown as indirectly holding 5,864,213 shares through Trust 1, 695,000 shares through “Trust 2,” and 695,000 shares through “Trust 3,” along with 1,599,750 shares held directly. The trusts are described as estate planning vehicles, and the reporting person disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest.